Although, many previous studies had proven the benefits of anti-VEGF therapy in the management of central involving DME in diabetes patients [12–14], there is a subgroup of patients who had persistent DME after the initiation of the medication [15]. This evidence concerns the gene VEGFA and diabetes mellitus.